Table 3.
Efficacy and Safety Outcomes of Early and Late Insulin Glargine Administration
| Efficacy Outcome | Early Administration (n = 51) | Late Administration (n = 51) | p value | |
|---|---|---|---|---|
| Time until CO2 >15 mEq/L, median (IQR), hr |
8.13 (5.75–11.12) |
8.02 (3.83–14.33) |
0.4161 | |
| Insulin infusion duration, median (IQR), hr | 16.2 (13.2–21.5) |
17.6 (10.6–22.3) |
0.8750 | |
| Insulin glargine dose, median (IQR), units/kg | 0.5 (0.3–0.5) | 0.5 (0.3–0.5) | 0.9546 | |
| Hospital LOS, median (IQR), days | 2 (1–3) | 2 (1–3) | 0.9068 | |
| PICU LOS, median (IQR), days | 1 (1–1) | 1 (1–1) | 0.8174 | |
| Safety Outcome | Early Administration (n = 51) | Late Administration (n = 51) | Relative Risk (95% CI) | p value |
| Any adverse event, n (%) | 33 (65) | 36 (71) | 1.20 (0.68–2.11) | 0.5255 |
| Hypoglycemia, n (%) |
23 (45) | 22 (43) | 1.05 (0.68–1.62) | 0.8419 |
| Hypokalemia, n (%) |
21 (41) | 21 (41) | 1.00 (0.63–1.59) | 1.0000 |
| Cerebral edema, n (%) | 1 (1) | 0 (0) | ||
| Hypoglycemia and hypokalemia within the same admission, n (%) | 11 (22) | 7 (14) | 1.57 (0.66–3.73) | 0.2988 |
CO2, serum sodium bicarbonate concentration; LOS, length of stay; PICU, pediatric intensive care unit